Impact of treatment patterns and sequencing on clinical and economic outcomes in patients with metastatic urothelial cancer: IMPACT UC II study.

ABSTRACT:

Importance

Real-world data about treatment sequencing and economic and clinical outcomes in patients with metastatic urothelial cancer (mUC) are limited.

Objective

The IMPACT UC II study evaluated real-world overall survival (OS), first-line (1L) to second-line (2L) progression, and healthcare resource utilization (HCRU) and costs in patients with mUC before US approval of avelumab 1L maintenance in June 2020.

Design

Retrospective study.

Setting

US insurance claims data from the Optum Research Database.

Participants

Adults diagnosed with mUC from July 2015 to June 2020, observed until death, disenrollment, or study end (August 2021).

Intervention(s) or exposure(s)

Three cohorts were defined based on 1L treatment received: cisplatin-based chemother

SUBMITTER: Bilen MA 

PROVIDER: S-EPMC12517744 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature